Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
159 SAR | +0.89% |
|
-3.64% | -7.45% |
12/06 | Dallah Healthcare Maintains Q1 Dividend | MT |
15/05 | Dallah Healthcare Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- The company returns high margins, thereby supporting business profitability.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an expected P/E ratio at 35.67 and 29.85 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.45% | 4.1B | - | ||
-32.30% | 13.7B | B+ | ||
+3.98% | 11.72B | B+ | ||
-3.60% | 11.51B | B | ||
+8.56% | 10.56B | B+ | ||
+26.78% | 8.52B | B | ||
-10.32% | 7.09B | A- | ||
+7.53% | 6.81B | B- | ||
+8.41% | 6.48B | D | ||
0.00% | 4.89B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4004 Stock
- Ratings Dallah Healthcare Company